Stockreport

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Surrozen, Inc.  (SRZN) 
PDF Substantial enrollment progress in Phase 1b trial of SZN-043 in severe alcohol-associated hepatitis patients with proof-of-concept data expected in the first half of 202 [Read more]